Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
230.18
+6.15 (2.75%)
Oct 26, 2026, 10:32 AM EDT - Market open
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 30 analysts polled by S&P Global, Alnylam Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $367.78. The average 1-year stock price forecast is 59.78% higher than the current stock price, while the lowest is $250 (+8.61%) and the highest is $536 (+132.86%).
Price Target: $367.78 (+59.78%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 14 | 14 | 16 | 16 | 17 |
| Buy | 7 | 7 | 8 | 7 | 6 | 6 |
| Hold | 8 | 8 | 6 | 6 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 30 | 29 | 28 | 29 | 29 | 30 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Buy Maintains $482 | Buy | Maintains | $482 | +109.40% | Oct 21, 2026 |
| UBS | UBS | Buy Maintains $550 → $354 | Buy | Maintains | $550 → $354 | +53.79% | Oct 14, 2026 |
| Wells Fargo | Wells Fargo | Hold Maintains $256 → $253 | Hold | Maintains | $256 → $253 | +9.91% | Oct 14, 2026 |
| Citi | Citi | Buy Maintains $340 → $320 | Buy | Maintains | $340 → $320 | +39.02% | Oct 14, 2026 |
| Barclays | Barclays | Buy Maintains $450 | Buy | Maintains | $450 | +95.50% | Oct 13, 2026 |
Financial Forecast
Revenue This Year
5.48B
from 3.71B
Increased by 47.54%
Revenue Next Year
6.92B
from 5.48B
Increased by 26.31%
EPS This Year
8.83
from 5.08
Increased by 73.77%
EPS Next Year
12.35
from 8.83
Increased by 39.92%
EPS and Forward PE are based on non-GAAP adjusted numbers.